Schizophrenia/Psychosis

Can ultra-low-carb eating ease schizophrenia symptoms? Evidence suggests metabolic gains and modest mood shifts, but no cure—here’s what studies show.

Learn how to spot catatonia quickly, use BFCRS screening, and safely treat with lorazepam or ECT while preventing complications.

Early psychosis screening in teens and young adults helps catch overlooked symptoms sooner.

FDA clears Bysanti, a novel atypical antipsychotic for acute bipolar I and schizophrenia, leveraging Fanapt data; US launch planned 2026.

The FDA accepts Teva’s once-monthly olanzapine injection for schizophrenia, promising steadier adherence without mandatory 3-hour monitoring.

Explore how seizure control, antiepileptics, and surgery can trigger psychosis in epilepsy, and what guides diagnosis and treatment.

Denovo teams with Orygen to test DB103, a glutamate-targeting therapy, in a phase 2 youth trial for early psychosis.

Physical activity boosts fitness, strength, and mental health in schizophrenia, cutting cardiometabolic risk and symptoms—especially with supervised, personalized programs in care.

Therapeutic drug monitoring revolutionizes psychiatric care, enhancing treatment precision and patient outcomes through real-time data and personalized medicine strategies.

In this CME article, explore the groundbreaking role of muscarinic cholinergic receptors in schizophrenia treatment, highlighting innovative therapies like KarXT for improved patient outcomes.

BioXcel Therapeutics submits an sNDA to the FDA for Igalmi to treat agitation in bipolar disorder and schizophrenia at home.

Cobenfy's innovative approach to treating schizophrenia marks a significant shift in psychiatric care.

Explore the unique mood-stabilizing properties of antiepileptics like lamotrigine, valproic acid, and carbamazepine in bipolar disorder treatment.

Research reveals that reducing anticholinergic burden can significantly enhance cognitive function in patients with psychosis, offering new treatment insights.

A clinical trial reveals challenges in assessing schizophrenia symptoms due to cultural and language differences, highlighting the need for improved measurement tools.

Reviva Pharmaceuticals reveals promising clinical trial data on brilaroxazine, highlighting its potential to treat negative symptoms in schizophrenia.

Explore the complex relationship between epilepsy and psychosis, including forced normalization and treatment strategies for affected patients.

NTX-253 enters phase 1 trials, exploring a novel approach to schizophrenia treatment with potential for improved safety and efficacy.

Xanomeline/trospium emerges as a groundbreaking schizophrenia treatment, showcasing efficacy and safety while highlighting challenges in clinical adoption.

MapLight Therapeutics advances treatment for Alzheimer disease psychosis with FDA Fast Track designation for ML-007C-MA, targeting hallucinations and delusions.

Explore innovative treatments for schizophrenia, depression, and dementia, focusing on new medications and holistic care approaches for better patient outcomes.

Syremis Therapeutics advances innovative drugs ST-905 and ST-901 for schizophrenia and major depressive disorder, aiming to transform mental health treatment.

Cobenfy gains NMPA approval in China, offering a groundbreaking treatment for schizophrenia with a unique mechanism and improved symptom management.

Reviva Pharmaceuticals announced FDA recommendations from their pre-NDA meeting on brilaroxazine for schizophrenia.

Explore innovative strategies for managing schizophrenia, focusing on novel treatments that address negative and cognitive symptoms beyond traditional antipsychotics.